

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEX01623

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?): 2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 09:33:36 ON 28 APR 2006

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:33:46 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5
DICTIONARY FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5

New CAS Information Use Policies. enter **HELP USAGE TERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDENTL, is now
* available and contains the CA role and document type information.
*****
*****
```


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10619777core1.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-13 8-12 10-11 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 8-12 9-10 10-11

exact bonds :

2-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10619777core2.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-13 8-12 10-11 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 8-12 9-10 10-11

exact bonds :


2-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L2 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10619777core3.str



chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-13 8-12 10-11 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
5-7 6-10 7-8 8-9 8-12 9-10 10-11
exact bonds :
2-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L3 STRUCTURE UPLOADED

=> s L1
SAMPLE SEARCH INITIATED 09:34:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1147 TO 2253
PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L1

```

=> s L2
SAMPLE SEARCH INITIATED 09:34:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -           4 TO ITERATE

100.0% PROCESSED      4 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   4 TO      200
PROJECTED ANSWERS:      0 TO      0

L5      0 SEA SSS SAM L2

=> s L3
SAMPLE SEARCH INITIATED 09:34:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -           4 TO ITERATE

100.0% PROCESSED      4 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   4 TO      200
PROJECTED ANSWERS:      0 TO      0

L6      0 SEA SSS SAM L3

=> sel L4
E1 THROUGH E2 ASSIGNED

=> file medline capplus biosis
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY          SESSION
FULL ESTIMATED COST          1.54          1.75

FILE 'MEDLINE' ENTERED AT 09:34:55 ON 28 APR 2006

FILE 'CAPPLUS' ENTERED AT 09:34:55 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:34:55 ON 28 APR 2006
Copyright (c) 2006 The Thomson Corporation


=> s E1-E3
'E3' NOT FOUND
The E# entered is not currently defined.

=> s E1-E2
L7      1 (188897-09-8/BI OR 188897-12-3/BI)

=> d L7 ti abs bib

L7      ANSWER 1 OF 1 CAPPLUS COPYRIGHT 2006 ACS on STN
TI      Synthesis of some conformationally-constrained glutamate mimics of
N-{5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-
d]pyrimidin-6-yl)ethyl[thien-2-ylcarbonyl]-L-glutamic acid (LY254155)
GI

```



AB Several new analogs I (R = cis-CO₂H, trans-CO₂H, H), II, and III of the active title antitumor agent LY254155 have been prepared in which the glutamate moiety has been replaced with conformationally-constrained azetidine and cyclopropane mimics. None of these new analogs exhibited significant cell growth inhibitory activity.

AN 1997:181706 CAPLUS

DN 126:277728

TI Synthesis of some conformationally-constrained glutamate mimics of N-[5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]thien-2-ylcarbonyl]-L-glutamic acid (LY254155)

AU Taylor, Edward C.; Hu, Baihua

CS Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA

SO Heterocycles (1997), 45(2), 241-253

CODEN: HTCYAM; ISSN: 0385-5414

PB Japan Institute of Heterocyclic Chemistry

DT Journal

LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

8.36 10.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-0.75 -0.75

FILE 'STNGUIDE' ENTERED AT 09:35:44 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 21, 2006 (20060421/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST	0.06	10.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 09:36:10 ON 28 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEX01623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 8 JAN 30 Saved answer limit increased
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 11 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16 MAR 01 INSPEC reloaded and enhanced
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006
NEWS 19 MAR 22 EMBASE is now updated on a daily basis
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 23 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 09:37:38 ON 28 APR 2006

=> file patents
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
TOTAL
SESSION
0.42
0.42
FULL ESTIMATED COST

FILE 'CAOLD' ENTERED AT 09:38:49 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 09:38:49 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 09:38:49 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CROPU' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DGENE' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DPCI' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'ENCOMPPAT' ENTERED AT 09:38:49 ON 28 APR 2006

EnComppat compilation and indexing Copyright 2006
Elsevier Inc. All rights reserved.

FILE 'EPFULL' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'FRANCEPAT' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 INPI

FILE 'FRFULL' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE 'FSTA' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'GBFULL' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE 'IFIPAT' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPATENTS' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd.

FILE 'INPADOC' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 European Patent Office, Vienna (EPO)

FILE 'JAPIO' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Japanese Patent Office (JPO) - JAPIO

FILE 'KOREAPAT' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 KIPI

FILE 'LITALERT' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'NTIS' ENTERED AT 09:38:49 ON 28 APR 2006
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2006)

FILE 'PAPERCHEM2' ENTERED AT 09:38:49 ON 28 APR 2006
Paperchem2 compilation and indexing Copyright 2006
Elsevier Inc. All rights reserved.

FILE 'PATDD' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT 2006 (C) Deutsches Patent- und Markenamt (DPMA)

FILE 'PATDPA' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (c) 2006 Deutsches Patent- und Markenamt / FIZ Karlsruhe (DPMA/FIZ KA)

FILE 'PATDPAPFULL' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 DPMA

FILE 'PATDPASPC' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Deutsches Patent- und Markenamt / FIZ Karlsruhe (DPMA/FIZ KA)

FILE 'PCTFULL' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE 'PCTGEN' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 WIPO

FILE 'PIRA' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Pira International

FILE 'PROUSDDR' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'PS' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Thieme on STN

FILE 'RAPRA' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 RAPRA Technology Ltd.

FILE 'RDISCLOSURE' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Kenneth Mason Publications Ltd.

FILE 'RUSSIAPAT' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 FIPS

FILE 'SYNTHLINE' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'TULSA' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 The University of Tulsa (UTULSA)

FILE 'USPATFULL' ENTERED AT 09:38:49 ON 28 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:38:49 ON 28 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION


FILE 'WPIFV' ENTERED AT 09:38:49 ON 28 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S (188897-09-8/BI OR 188897-12-3/BI)
5 FILES SEARCHED...
6 FILES SEARCHED...
30 FILES SEARCHED...
L1 1 (188897-09-8/BI OR 188897-12-3/BI)

=> d L1 ti abs bib

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of some conformationally-constrained glutamate mimics of
N-[5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-
d]pyrimidin-6-yl)ethyl[thien-2-ylcarbonyl]-L-glutamic acid (LY254155)
GI



AB Several new analogs I (R = cis-CO₂H, trans-CO₂H, H), II, and III of the active title antitumor agent LY254155 have been prepared in which the glutamate moiety has been replaced with conformationally-constrained azetidine and cyclopropane mimics. None of these new analogs exhibited significant cell growth inhibitory activity.

AN 1997:181706 CAPLUS

DN 126:277728

TI Synthesis of some conformationally-constrained glutamate mimics of N-[5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl[thien-2-ylcarbonyl]-L-glutamic acid (LY254155)

AU Taylor, Edward C.; Hu, Baihua

CS Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA

SO Heterocycles (1997), 45(2), 241-253

CODEN: HTCYAM; ISSN: 0385-5414

PB Japan Institute of Heterocyclic Chemistry

DT Journal

LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	79.32	79.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 09:41:57 ON 28 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEX01623

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 11:47:03 ON 28 APR 2006

=> file registry
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
TOTAL
SESSION
0.21
0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:47:18 ON 28 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5
DICTIONARY FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```


Structure search iteration limits have been increased. See **HELP SLIMITS** for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10619777coregeneric.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-12 8-14 10-11 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 8-14 9-10 10-11

exact bonds :

2-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> s L1

SAMPLE SEARCH INITIATED 11:47:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2956 TO 4604
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> file medline caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.44	0.65

FILE 'MEDLINE' ENTERED AT 11:47:52 ON 28 APR 2006

FILE 'CAPLUS' ENTERED AT 11:47:52 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (MMP-13 or meatlloprot? or (collagenase(w)3))
L3 2264 (MMP-13 OR MEATLLOPROT? OR (COLLAGENASE(W) 3))

=> s L3 and (cancer or neoplasia or ?rolifera?)
L4 440 L3 AND (CANCER OR NEOPLASIA OR ?ROLIFERA?)

=> s L4 and Cox-2
L5 7 L4 AND COX-2

=> dup rem L5
PROCESSING COMPLETED FOR L5
L6 7 DUP REM L5 (0 DUPLICATES REMOVED)

=> d L6 1-7 ti abs bib

L6 ANSWER 1 OF 7 MEDLINE on STN
TI Development and phenotypic characterization of a high density in vitro model of auricular chondrocytes with applications in reconstructive plastic surgery.
AB Cultivation of phenotypically stable auricular chondrocytes will have applications in autologous chondrocyte transplantation and reconstructive surgery of cartilage. Chondrocytes grown in monolayer culture rapidly dedifferentiate assuming a fibroblast-like morphology and lose their cartilage-specific pattern of gene expression. Three-dimensional high-density culture models mimic more closely the in vivo conditions of cartilage. Therefore, this study was undertaken to test whether the high-density cultures might serve as a suitable model system to acquire phenotypically and functionally differentiated auricular chondrocytes from porcine cartilage. Freshly isolated porcine auricular chondrocytes were cultured for 7 passages in monolayer culture. From each passage (passage 0 and 1-7) cells were introduced to high-density cultures and examined by transmission electron microscopy. Western blotting was used to analyse the expression of cartilage-specific markers, such as collagen type II and cartilage specific proteoglycan, fibronectin, cell adhesion and signal transduction receptor beta1-integrin, matrix metalloproteinases (MMP-9, MMP-13), cyclo-oxygenase (COX)-2 and the apoptosis commitment marker, activated caspase-3. When dedifferentiated auricular chondrocytes from monolayer passages 0-4 were cultured in high-density culture, they recovered their chondrocytic phenotype and formed cartilage nodules surrounded by fibroblast-like cells and synthesised collagen type II, proteoglycans, fibronectin and beta1-integrins. However, chondrocytes from monolayer passages 5-7 did not redifferentiate to chondrocytes even when transferred to high-density culture, and did not synthesize a chondrocyte-specific extracellular matrix. Instead, they produced increasing amounts of MMP-9, MMP-13, COX-2, activated caspase-3 and underwent apoptosis. Three-dimensional high-density cultures may therefore be used to obtain sufficient quantities of fully differentiated auricular chondrocytes for autologous chondrocyte transplantation and reconstructive plastic surgery.

AN 2006106071 MEDLINE

DN PubMed ID: 16493577

TI Development and phenotypic characterization of a high density in vitro model of auricular chondrocytes with applications in reconstructive plastic surgery.

AU Haisch A; Marzahn U; Mobasher A; Schulze-Tanzil G; Shakibaei M

CS Department of Otorhinolaryngology, Head and Neck Surgery, Charite Medicine University Berlin, Campus Benjamin Franklin, Berlin, Germany..
andreas.haisch@charite.de

SO Histology and histopathology, (2006 May) Vol. 21, No. 5, pp. 467-76.
Journal code: 8609357. E-ISSN: 1699-5848.

CY Spain

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200604

ED Entered STN: 23 Feb 2006

Last Updated on STN: 14 Apr 2006

Entered Medline: 13 Apr 2006

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Nucleic acids and polypeptides associated with osteoarthritis and diagnostic and therapeutic uses thereof

AB The invention claims high-throughput functional screening assays that identify genes and gene products that are associated with the pathogenesis of osteoarthritis (OA) in human chondrocytes. In addition, the invention claims genes and gene products identified by such functional assays. The genes and gene products provided herein are useful *inter alia* for diagnosing OA in individuals and as drug targets for identifying drugs to treat OA. CDNA libraries from OA chondrocytes were annotated and mined by searching the sequence annotations for keywords. Gene expression data from DNA microarrays were also mined to identify OA associated genes. A set of about 1200 clones were expressed in chondrocyte cells and the transformants were screened for expression of OA marker genes by RT-PCR. The marker genes were C17, SMOC2, OSF-2 (periostin), MARCKS (myristoylated alanine-rich protein kinase C substrate), retinoic acid receptor β , zinc finger protein Zic1, BASP1 (brain abundant membrane attached signal protein 1), DIM1, aggrecanase-1, collagens type I, Iia, and X, iNOS, Cox-2, aggrecan and decorin. Sixty-three candidate genes were identified in the RT-PCR screen. Another high throughput screen identified seven candidate genes that induce clonal proliferation of chondrocyte clusters similar to clusters observed in OA cartilage.

AN 2004:905932 CAPLUS

DN 141:389861

TI Nucleic acids and polypeptides associated with osteoarthritis and diagnostic and therapeutic uses thereof

IN Bodian, Dale Lesley; Daouti, Sherif; Kumar, Chandrika Saidapet; Latario, Brian Jude; Quintavalla, Joseph

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092413	A2	20041028	WO 2004-EP4055	20040416
	WO 2004092413	A3	20050616		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1618209	A2	20060125	EP 2004-727860	20040416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-463933P	P	20030418		
	WO 2004-EP4055	W	20040416		

L6 ANSWER 3 OF 7 MEDLINE on STN

TI Differentially up-regulated genes in proliferating porcine

AB neonatal pancreas cells caused by epidermal growth factor.

Pancreatic duct cells are considered to be a major source for beta-cell regeneration or neogenesis. Although epidermal growth factor (EGF) is a well-known important growth factor for pancreas development, the control of pancreatic duct cell growth and differentiation by EGF is poorly understood. In this study, we focused on identifying the genes that were differentially up-regulated in response to EGF stimulation using monolayer cultured porcine neonatal pancreas cells. Cells were obtained from 1 to 3 day old pigs, dispersed and cultured for 8 days. Monolayer cultured porcine pancreas cells were comprised of duct cells and some endocrine and mesenchymal cells (75.2 +/- 15.1, 19.6 +/- 4.9, and 9.5 +/- 3.1%, respectively). After 16 h in serum free media, cells were treated with 100 microg/L EGF for 24 h. Differentially expressed genes were screened by subtractive hybridization. (3)H-thymidine uptake was significantly increased by EGF with time (untreated vs. 24 h treated, untreated vs. 48 h treated: 305.5 +/- 3.5 cpm vs. 380.3 +/- 17.3 cpm (P < 0.05), 309.2 +/- 4.51 vs. 929 +/- 9.19 cpm, (P < 0.005), respectively). Three hundred and fifty cDNA clones were obtained by subtractive hybridization and the inserts were confirmed in 161 colonies and then sequenced. Finally, we found increased mRNA expression of five unknown and five known genes, including cytochrome c oxidase subunit I (COI), cyclooxygenase-2 (COX-2), matrix metalloproteinase-13 (MMP-13), Wiskott-Aldrich syndrome protein interacting protein (WASPIP), and hyaluronan synthase-2 (HAS-2). We confirmed the up-regulation of these genes by Northern blot and semi-quantitative RT-PCR at various time points. The present findings opened new targets for the research on the mechanisms of pancreatic duct cell proliferation by EGF.

Copyright 2003 Wiley-Liss, Inc.

AN 2004041791 MEDLINE

DN PubMed ID: 14743394

TI Differentially up-regulated genes in **proliferating** porcine neonatal pancreas cells caused by epidermal growth factor.

AU Jeon Sung Yoon; Baek Kwang-Hyun; Kim Yong-Soo; Park Chung-Gyu; Kwon Hyuk Sang; Ko Seung Hyun; Song Ki-Ho; Yoo Soon Jib; Son Hyun Shik; Cha Bong Yun; Lee Kwang Woo; Son Ho Young; Kang Sung Koo; Yoon Kun-Ho

CS Department of Endocrinology and Metabolism, Immunology & Cell Biology Core Laboratory, The Catholic University of Korea, Seoul, Korea.

SO Journal of cellular biochemistry, (2004 Feb 1) Vol. 91, No. 2, pp. 354-64. Journal code: 8205768. ISSN: 0730-2312.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200410

ED Entered STN: 27 Jan 2004

Last Updated on STN: 20 Oct 2004

Entered Medline: 19 Oct 2004

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Differentially up-regulated genes in **proliferating** porcine neonatal pancreas cells caused by epidermal growth factor

AB Pancreatic duct cells are considered to be a major source for β -cell regeneration or neogenesis. Although epidermal growth factor (EGF) is a well-known important growth factor for pancreas development, the control of pancreatic duct cell growth and differentiation by EGF is poorly understood. In this study, we focused on identifying the genes that were differentially up-regulated in response to EGF stimulation using monolayer cultured porcine neonatal pancreas cells. Cells were obtained from 1 to 3 day old pigs, dispersed and cultured for 8 days. Monolayer cultured porcine pancreas cells were comprised of duct cells and some endocrine and mesenchymal cells (75.2 \pm 15.1, 19.6 \pm 4.9, and 9.5 \pm 3.1%, resp.).

After 16 h in serum free media, cells were treated with 100 μ g/L EGF for 24 h. Differentially expressed genes were screened by subtractive hybridization. 3 H-thymidine uptake was significantly increased by EGF

with time (untreated vs. 24 h treated, untreated vs. 48 h treated: 305.5 ± 3.5 cpm vs. 380.3 ± 17.3 cpm ($P < 0.05$), 309.2 ± 4.51 vs. 929 ± 9.19 cpm, ($P < 0.005$), resp.). Three hundred and fifty cDNA clones were obtained by subtractive hybridization and the inserts were confirmed in 161 colonies and then sequenced. Finally, we found increased mRNA expression of five unknown and five known genes, including cytochrome c oxidase subunit I (COI), cyclooxygenase-2 (COX-2), matrix metalloproteinase-13 (MMP-13), Wiskott-Aldrich syndrome protein interacting protein (WASPIP), and hyaluronan synthase-2 (HAS-2). We confirmed the up-regulation of these genes by Northern blot and semi-quant. RT-PCR at various time points. The present findings opened new targets for the research on the mechanisms of pancreatic duct cell proliferation by EGF.

AN 2004:140987 CAPLUS
DN 140:315630
TI Differentially up-regulated genes in proliferating porcine neonatal pancreas cells caused by epidermal growth factor
AU Jeon, Sung Yoon; Baek, Kwang-Hyun; Kim, Yong-Soo; Park, Chung-Gyu; Kwon, Hyuk Sang; Ko, Seung Hyun; Song, Ki-Ho; Yoo, Soon Jib; Son, Hyun Shik; Cha, Bong Yun; Lee, Kwang Woo; Son, Ho Young; Kang, Sung Koo; Yoon, Kun-Ho
CS Department of Endocrinology and Metabolism, Immunology & Cell Biology Core Laboratory, The Catholic University of Korea, Seoul, S. Korea
SO Journal of Cellular Biochemistry (2003), Volume Date 2004, 91(2), 354-364
CODEN: JCEBD5; ISSN: 0730-2312
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = 0, SOt (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOk (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety, useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepared. E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzeneboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001 μ M to 20.0 μ M in whole blood assay for LTE4.

AN 2002:594822 CAPLUS
DN 137:154857
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060875	A1	20020808	WO 2001-IB2341	20011206
	WO 2002060875	C1	20030731		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2436535	AA	20020808	CA 2001-2436535	20011206
	EP 1355884	A1	20031029	EP 2001-273556	20011206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300360	A	20031215	EE 2003-360	20011206
	BR 2001016852	A	20040225	BR 2001-16852	20011206
	JP 2004520386	T2	20040708	JP 2002-561026	20011206
	CN 1518542	A	20040804	CN 2001-823071	20011206
	NZ 526453	A	20050128	NZ 2001-526453	20011206
	US 2002193612	A1	20021219	US 2002-62813	20020131
	US 6649633	B2	20031118		
	ZA 2003004894	A	20040624	ZA 2003-4894	20030624
	US 2004048903	A1	20040311	US 2003-613988	20030702
	US 6953810	B2	20051011		
	BG 108038	A	20040730	BG 2003-108038	20030728
	NO 2003003397	A	20030919	NO 2003-3397	20030730
PRAI	US 2001-265492P	P	20010131		
	WO 2001-IB2341	W	20011206		
	US 2002-62813	A3	20020131		

OS MARPAT 137:154857

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation
 AB The active form of vitamin D3, 1 α ,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is key mediator of calcium homeostasis and is a component of the complex homeostatic system of the skin. 1,25-(OH)2D3 regulates cellular differentiation and proliferation and has broad potential as an anticancer agent. Oligonucleotide microarrays were used to assess profiles of target gene regulation at several points over a 48 h period by the low calcemic 1,25-(OH)2D3 analog EB1089 in human SCC25 head and neck squamous carcinoma cells. One hundred fifty-two targets were identified, composed of 89 up- and 63 down-regulated genes distributed in multiple profiles of regulation. Results are consistent with EB1089 driving SCC25 cells toward a less malignant phenotype, similar to that of basal keratinocytes. Targets identified control inter- and intracellular signaling, G protein-coupled receptor function, intracellular redox balance, cell adhesion, and extracellular matrix composition, cell cycle progression, steroid metabolism, and more than 20 genes modulating immune system function. The data indicate that EB1089 performs three key functions of a cancer chemoprevention agent; it is antiproliferative, it induces cellular differentiation, and has potential genoprotective effects. While no evidence was found for gene-specific differences in efficacy of 1,25-(OH)2D3 and EB1089, gene regulation by 1,25-(OH)2D3 was generally more transient. Treatment of cells with 1,25-(OH)2D3 and the cytochrome P 450 inhibitor ketoconazole produced profiles of regulation essentially identical to those observed with EB1089 alone, indicating that the more sustained regulation by EB1089 was

due to its resistance to inactivation by induced 24-hydroxylase activity. This suggests that differences in action of the two compds. arise more from their relative sensitivities to metabolism than from differing effects on VDR function.

AN 2002:431768 CAPLUS

DN 138:50194

TI Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation

AU Lin, Roberto; Nagai, Yoshihiko; Sladek, Robert; Bastien, Yolande; Ho, Joanne; Petrecca, Kevin; Sotiropoulou, Georgia; Diamandis, Eleftherios P.; Hudson, Thomas J.; White, John H.

CS Department of Physiology, McGill University, Montreal, QC, H3G 1Y6, Can.

SO Molecular Endocrinology (2002), 16(6), 1243-1256

CODEN: MOENEN; ISSN: 0888-8809

PB Endocrine Society

DT Journal



LA English

RE.CNT 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Synthesis of arylsulfonyl-pyranyl-hydroxamic acids as MMP inhibitors

GI



AB Title compds. I [X = O, S0-2, NR3; Z = alkoxy, amino, alkyl; R1-2, R5-6 = H, CN, alk(en/yn)yl, (hetero)arylalken(yn)yl, etc.; R4 = H, alkyl; R7-8 = H, OH, halo, CN, alk(en/yn)yl, (alkyl)amino, etc.] were prepared. E.g., common intermediate II (Y = OH, preparation given) was converted to aryloxy derivs. with a substituted benzyl halide (DMF, Cs2CO3, room temperature) and converted to N-hydroxy amide I via an intermediate N-hydroxy-N-allyl amide (a. DCM, allylhydroxylamine, HOBT, EDCI; b. CH3CNaq, Pd(PPh3)4, HCO2H, Et3N). I exhibit collagenase activity with IC50 ≤ 100 μM in at least one of the collagenase assays conducted (no data). I are useful in the treatment of arthritis, cancer, and other diseases involving the dysregulated production/release of prolyl endopeptidases such as aggrecanase and other diseases characterized by matrix metalloproteinase activity.

AN 2001:729766 CAPLUS

DN 135:288692

TI Synthesis of arylsulfonyl-pyranyl-hydroxamic acids as MMP inhibitors

IN Noe, Mark Carl

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 52 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1138680	A1	20011004	EP 2001-302436	20010316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

CA 2342271	AA	20010929	CA 2001-2342271	20010327
US 2002019534	A1	20020214	US 2001-818056	20010327
US 6608104	B2	20030819		
JP 2001316383	A2	20011113	JP 2001-95089	20010329
JP 3645825	B2	20050511		
BR 2001001241	A	20020226	BR 2001-1241	20010329
PRAI US 2000-192963P	P	20000329		

OS MARPAT 135:288692

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s L4 and ((Cox-2) or (cyclooxygenase(w)2)

UNMATCHED LEFT PARENTHESIS 'AND ((COX-2'

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s L4 and ((Cox-2) or (cyclooxygenase(w)2))

L7 8 L4 AND ((COX-2) OR (CYCLOOXYGENASE(W) 2))

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.30	45.95
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

FILE 'REGISTRY' ENTERED AT 11:52:56 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5
DICTIONARY FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10619777coregeneric2.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-12 8-14 10-11 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 8-14 9-10 10-11

exact bonds :

2-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L8 STRUCTURE UPLOADED

=> s L8

SAMPLE SEARCH INITIATED 11:53:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS
SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2956 TO 4604
PROJECTED ANSWERS: 3 TO 163

L9 3 SEA SSS SAM L8

=> sel L9

E1 THROUGH E3 ASSIGNED

=> d L9 1-3 ti abs bib
'TI' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'BIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual

fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.


The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):
ENTER DISPLAY FORMAT (IDE):ide

L9 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 211938-02-2 REGISTRY
ED Entered STN: 01 Oct 1998
CN 2,4(1H,3H)-Quinazolinedione, 6-[(4-cyclobutyl-2-thiazolyl)ethynyl]-3-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H13 N7 O2 S
SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 188897-12-3 REGISTRY
 ED Entered STN: 08 May 1997
 CN 2-Azetidinecarboxylic acid, 1-[[5-[[2-[(2,2-dimethyl-1-oxopropyl)amino]-1,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethynyl]-2-thienyl]carbonyl]-4-(hydroxymethyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H25 N5 O6 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 188897-09-8 REGISTRY
 ED Entered STN: 08 May 1997
 CN 2-Azetidinecarboxylic acid, 1-[[5-[[2-[(2,2-dimethyl-1-oxopropyl)amino]-1,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethynyl]-2-thienyl]carbonyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H23 N5 O5 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus			
COST IN U.S. DOLLARS	SINCE FILE		TOTAL
FULL ESTIMATED COST	ENTRY		SESSION
	8.01		53.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE		TOTAL
CA SUBSCRIBER PRICE	ENTRY		SESSION
	0.00		-3.75

FILE 'CAPLUS' ENTERED AT 11:54:48 ON 28 APR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2006 VOL 144 ISS 19
 FILE LAST UPDATED: 27 Apr 2006 (20060427/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s E1-E3
 1 188897-09-8/BI
 1 188897-12-3/BI
 1 211938-02-2/BI
 L10 2 (188897-09-8/BI OR 188897-12-3/BI OR 211938-02-2/BI)

=> d L10 1-2 ti abs bib

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of 2-ethynylthiazole derivatives as leukotriene antagonists
 GI



I



II

AB The title compds. [I; R1, R2 = H, halo, (un)substituted alkyl or cycloalkyl; or R1 and R2 together form a ring; A = (un)substituted Ph, pyridyl, furyl, thienyl, benzofuranyl, benzo[b]thienyl, benzoxazolyl, benzothiazolyl, pyrido[1,2-a]pyrimidinyl, quinazolyl, benzotriazinyl, or 2H-chromenyl; G1 = O, CO, C.tplbond.C, (un)substituted NR3CO, NR4, NR5SO2, SO2NR6, CONR7, C(:CHR8), CR9:CR10; R3 - R7 = H, OH, (un)substituted alkyl; R8 = cyano, CO2H, (un)substituted alkoxy carbonyl; R9, R10 = H, halo, (un)substituted alkyl, cycloalkyl, or aryl; or R9 and R10 together form a ring; G2 = (un)substituted Ph, pyridyl, thiazolyl, isoxazolyl, thienyl, or pyrimidinyl, etc.; m, n = 0, 1; Q = CO2H, (un)substituted alkoxy carbonyl, 5-tetrazolylaminocarbonyl, (un)substituted 5-tetrazolyl, 1,2,3-triazolyl, 2,4-dioxothiazolidin-5-ylidene, or 4-oxo-2-thioxothiazolidin-5-ylidene, etc.; excluding the case where m = n = 0 and Q = CO2H or alkoxy carbonyl], which show photostability and activities of both leukotriene antagonism and inhibition of histamine release from mast cells, are prepared A therapeutic or preventive drug containing I as the active ingredient for the treatment of allergies or leukotriene and/or histamine-related diseases is claimed. Thus, 2-fluoro-4-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoic acid was refluxed with SOC12 in the presence of DMF in PhMe for 3 h and then condensed with 3-[2-(4-cyclobutyl-2-thiazolyl)ethynyl]aniline in the presence of Et3N, followed by treatment with anisole/CF3CO2H to give the title compound, ethynylthiazole containing triazole derivative (II). II in vitro

showed IC50 5.7+10-10 M for inhibiting leukotriene D4-induced contraction of guinea pig's ileum and 9.3+10-9 M for inhibiting histamine release from rat's mast cells and in vivo inhibited leukotriene D4-induced contraction of guinea pig's air way with ID50 of 0.4 mg/kg p.o. An inhalant and capsule formulation containing II were prepared

AN 1998:493329 CAPLUS

DN 129:189329

TI Preparation of 2-ethynylthiazole derivatives as leukotriene antagonists

IN Nakayama, Atsushi; Takeda, Satoshi; Machinaga, Nobuo; Ogasawara, Tomomi; Naito, Hiroshi; Hasegawa, Masashi; Haruda, Makoto

PA Daiichi Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 121 pp.

CODEN: JKXXAF


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10195063	A2	19980728	JP 1997-286340	19971020
PRAI	JP 1996-278347	A	19961021		
OS	MARPAT 129:189329				

TI Synthesis of some conformationally-constrained glutamate mimics of N-[5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl[thien-2-ylcarbonyl]-L-glutamic acid (LY254155)
GI



AB Several new analogs I (R = cis-CO₂H, trans-CO₂H, H), II, and III of the active title antitumor agent LY254155 have been prepared in which the glutamate moiety has been replaced with conformationally-constrained azetidine and cyclopropane mimics. None of these new analogs exhibited significant cell growth inhibitory activity.

AN 1997:181706 CAPLUS

DN 126:277728

TI Synthesis of some conformationally-constrained glutamate mimics of N-[5-[2-(2-amino-3,4-dihydro-4-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl[thien-2-ylcarbonyl]-L-glutamic acid (LY254155)

AU Taylor, Edward C.; Hu, Baihua

CS Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA

SO Heterocycles (1997), 45(2), 241-253

CODEN: HTCYAM; ISSN: 0385-5414

PB Japan Institute of Heterocyclic Chemistry

DT Journal

LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

12.71	66.67
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-1.50	-5.25
-------	-------

FILE 'STNGUIDE' ENTERED AT 11:56:25 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 21, 2006 (20060421/UP) .

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

FULL ESTIMATED COST

0.06	66.73
------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

CA SUBSCRIBER PRICE

0.00	-5.25
------	-------

STN INTERNATIONAL LOGOFF AT 11:56:33 ON 28 APR 2006